Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Core Insights - Cingulate Inc. is focused on developing its lead Phase 3 asset CTx-1301 for ADHD treatment and exploring commercialization plans [1][3] - The company utilizes its proprietary Precision Timed Release™ (PTR™) drug delivery platform to create next-generation pharmaceutical products [1][3] - Cingulate is also evaluating additional therapeutic areas for its PTR technology, including anxiety disorders [3] Company Overview - Cingulate Inc. is a clinical-stage biopharmaceutical company headquartered in Kansas City [3] - The company aims to improve treatment outcomes for patients with conditions that require burdensome daily dosing regimens [3] - Cingulate's initial focus is on Attention Deficit/Hyperactivity Disorder (ADHD) [3]